What is PT-141 (bremelanotide) from an analytical standpoint?
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist. It was originally developed from the earlier melanocortin analogue melanotan-II and progressed through pharmaceutical development, with its receptor-agonist profile described in early reviews of the Palatin compound (PMID:15134289) and in broader surveys of melanocortin peptides (PMID:17584134). For laboratory identity work, the practical significance of this structure is that bremelanotide is a defined, cyclic sequence with a fixed theoretical monoisotopic and average mass, and a characteristic reversed-phase retention behaviour driven by its amphipathic character. A supplier's analytical package should let you reconcile the observed mass against the published, well-characterised structure. Because bremelanotide has been formally characterised in the peer-reviewed and regulatory literature — including its first regulatory approval as a therapeutic in another jurisdiction (PMID:31429064) — the expected analytical fingerprint is not ambiguous. That is a real advantage for buyers: unlike obscure novel sequences, an established melanocortin peptide can be cross-checked against literature mass and structural data. When evaluating a PT-141 supplier in Australia, treat the stated molecular formula and mass on the COA as a claim to be verified by the accompanying spectra, not accepted on trust. Any credible research-grade offering should present identity, purity and quantity as three separately measured, separately documented parameters. The remainder of this page walks through each of those data types and the acceptance framing a laboratory should apply, so that supplier comparison rests on analytical evidence rather than presentation.
What identity data should a PT-141 COA include?
Identity confirmation answers a single question: is the material in the vial actually bremelanotide? The primary evidence is mass spectrometry. Electrospray ionisation (ESI-MS) or MALDI-TOF should report an observed mass that agrees with the theoretical mass of the bremelanotide sequence within the instrument's stated tolerance. For a peptide of this size, deconvoluted ESI data and the expected charge-state envelope give high-confidence molecular-weight confirmation, while MALDI-TOF offers a rapid orthogonal cross-check. A rigorous supplier will also provide sequence-level confirmation via tandem mass spectrometry (MS/MS), where the observed fragment ions map onto the predicted b- and y-ion series of the cyclic heptapeptide backbone. Because bremelanotide is cyclic, ring-opening during fragmentation should be accounted for in the interpretation — a detail that distinguishes genuinely analytical documentation from a template. Identity should never rest on retention time alone; co-elution with an unrelated species is possible, so mass and, ideally, sequence data are the decisive evidence. The published characterisation of bremelanotide across its development programme (PMID:34436837) provides a reference point for the expected structure. When you request documentation from a PT-141 supplier in Australia, look for: the theoretical versus observed mass with the mass error stated; the ionisation technique named; and a legible spectrum or annotated peak list rather than a single number typed into a table. A COA that lists a mass with no supporting spectrum is an assertion, not a measurement. Orthogonal identity — combining HPLC retention with independent MS confirmation — is the standard a research laboratory should expect before accepting any lot into its inventory records.
How is PT-141 purity measured and what limits apply?
Purity is quantified separately from identity and is most commonly reported as chromatographic purity by reversed-phase HPLC with UV detection, expressed as the percentage of total integrated peak area attributable to the main peak. A meaningful purity figure is only interpretable alongside the method conditions: column chemistry, mobile-phase gradient, detection wavelength, and the integration and peak-threshold parameters used. Two suppliers reporting '99%' under different gradients or integration thresholds are not necessarily comparable, so the reported number should always be accompanied by the chromatogram. Related-substance and impurity profiling matters because synthetic peptides carry process-related impurities — truncated sequences, deletion peptides, and oxidised or deamidated variants — that a well-developed method should resolve from the main peak. Peak purity assessment using diode-array detection (DAD) helps confirm that the main peak is a single component and not a co-eluting pair, using purity-angle and purity-threshold metrics. Purity as area-percent is not the same as net peptide content: the material also contains counterions and residual water, so a complete package quantifies the counterion (commonly acetate or trifluoroacetate) and reports net peptide content separately. For an Australian research buyer, the acceptance framing to apply is: a stated purity specification with a defined limit; a chromatogram supporting the number; a related-substances summary; and counterion plus net-content figures so mass-based calculations in your own protocol are accurate. A supplier who publishes only a headline purity percentage, with no method and no chromatogram, has not given you enough to verify their claim independently.
How do you verify batch authenticity and lot traceability?
Traceability links the physical vial to its documentation. A credible PT-141 supplier assigns a unique lot number to each synthesis batch, and every analytical result — identity spectra, HPLC chromatogram, purity figure, counterion and water content — should reference that same lot. When your vial arrives, the lot number on the label should match the COA exactly; a mismatch, or a generic COA reused across multiple lots, undermines the entire documentation chain. Batch verification is strengthened by orthogonal methods: pairing HPLC-UV purity with an independent LC-MS run confirms both that the main peak is bremelanotide and that no significant unlabelled species dominates. Where a laboratory needs an added layer of assurance, independent confirmation of sample identity using a second, orthogonal technique — for example MALDI-TOF cross-checking ESI results — provides evidence that does not depend on a single instrument or a single laboratory. For bulk or multi-vial orders, per-lot documentation should demonstrate consistency across vials drawn from the same batch, with a batch report that cross-references each COA field. Australian buyers should also confirm practical fulfilment details that support record-keeping: local stock with tracked dispatch, clear batch labelling, and documentation supplied with or before the goods. Retaining the COA, chromatograms and spectra in your own laboratory notebook or LIMS creates a defensible audit trail. The overarching principle is simple: if a data point cannot be tied back to a named lot and a named method, it should not be relied upon when comparing suppliers or accepting material into a study.
What stability and storage documentation supports research use?
Analytical quality at the point of release is only part of the picture; how the peptide behaves over time and under handling conditions determines whether your recorded purity still applies when you use the material. Peptides can undergo characteristic degradation pathways including oxidation, deamidation, aggregation and hydrolysis, and a thorough supplier or laboratory will understand which pathways are relevant to a given sequence. Forced-degradation and stability study data, where available, show how the main peak and its impurity profile change under stress, giving confidence that the release specification is meaningful rather than a single snapshot. Water content, typically determined by Karl Fischer titration, is relevant both to accurate net-peptide quantification and to hydrolytic stability of the lyophilised solid. For lyophilised research peptides, documentation of the physical form and appropriate handling of the sealed, dry material supports reproducible reconstitution in your own workflow. Once reconstituted, solution stability depends on buffer, pH and container material — peptides can adsorb to glass and plastic surfaces, subtly reducing recovered concentration — so a supplier's analytical resources should acknowledge these considerations even though the buyer performs reconstitution. None of this constitutes usage guidance; it is quality-system information that lets a laboratory decide storage, re-test intervals and concentration-verification steps for itself. When comparing PT-141 suppliers in Australia, favour those whose documentation extends beyond a bare COA to include stability-relevant parameters such as water content and physical-form description, because these are what make your recorded identity and purity figures durable across the life of the lot in your laboratory.
How should an Australian laboratory compare PT-141 suppliers?
A structured comparison replaces price-first shopping with evidence-first evaluation. Build a short checklist and apply it identically to each supplier. First, identity: is there a named MS technique, a stated theoretical-versus-observed mass, and a legible spectrum — ideally with MS/MS sequence support? Second, purity: is chromatographic purity reported with the full HPLC method, an actual chromatogram, and a related-substances summary, plus DAD peak-purity confirmation? Third, quantity: are counterion identity and net peptide content reported so your mass calculations are correct? Fourth, traceability: does every result reference a single lot number that matches the vial label, with per-vial or per-lot consistency data for bulk orders? Fifth, fulfilment: is there local Australian stock with tracked dispatch and documentation supplied with the goods? Bremelanotide's structure is well established in the literature, including detailed characterisation across its clinical development programme (PMID:35147466) and its mechanism as a melanocortin receptor agonist (PMID:33455598), which means a supplier has no legitimate reason to withhold clear identity and purity data — the reference points are public. Treat vague or incomplete documentation as a negative signal in your comparison, not a neutral one. Keep copies of every COA and chromatogram you receive so you can audit consistency across repeat orders over time. This approach keeps supplier selection firmly in the domain of analytical chemistry and quality systems, where an Australian research laboratory can make a defensible, documented decision — and it applies equally to PT-141 and to any other research peptide in your catalogue.
Order Pt141 with documentation
If this guide helped you evaluate Pt141 for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Pt141 card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
What analytical documentation should come with research-grade PT-141?
At minimum: mass spectrometry identity data with theoretical versus observed mass, reversed-phase HPLC purity with the method and an actual chromatogram, a related-substances summary, counterion identity and net peptide content, and a unique lot number that matches the vial label. Stability-relevant data such as Karl Fischer water content strengthens the package.
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the research designation for bremelanotide, a synthetic cyclic melanocortin receptor agonist heptapeptide. Its structure is well characterised in the published literature, which makes independent analytical confirmation of identity and mass straightforward when a supplier releases spectra and chromatograms.
How do I confirm the PT-141 I received matches its COA?
Check that the lot number on the vial label matches the COA exactly, then confirm the COA reports identity by mass spectrometry, purity by HPLC with a supporting chromatogram, and net peptide content. Orthogonal LC-MS or MALDI-TOF cross-checks provide added assurance of batch authenticity.
Why does net peptide content differ from HPLC purity?
HPLC purity is the area-percent of the main peak among peptide-related species. Net peptide content accounts for non-peptide mass — counterions such as acetate or trifluoroacetate and residual water. Both figures are needed: purity for quality, net content for accurate mass-based calculations in your protocol.
Does ClaraScience provide documentation with Australian PT-141 orders?
Research-grade material should ship with per-lot analytical documentation, including identity and purity data referenced to a single lot number, from local Australian stock with tracked dispatch. Always retain the COA and chromatograms in your own records to maintain a defensible audit trail across repeat orders.
References
- PMID:15134289 — PT-141 Palatin — Curr Opin Investig Drugs — 2004
- PMID:17584134 — Melanocortins in the treatment of male and female sexual dysfunction — Curr Top Med Chem — 2007
- PMID:31429064 — Bremelanotide: First Approval — Drugs — 2019
- PMID:34436837 — Bremelanotide — 2012
- PMID:35147466 — Safety Profile of Bremelanotide Across the Clinical Development Program — J Womens Health (Larchmt) — 2022
- PMID:33455598 — The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women — CNS Spectr — 2022
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
